Table 1 Population characteristis of the study population according to pre- and post-diagnostic anticoagulant usage status
| Â | Pre-diagnostic status | Post-diagnostic status | |||||
|---|---|---|---|---|---|---|---|
No anticoagulation | Warfarin | Other anticoagulants | No anticoagulation | Warfarin | Other anticoagulants | ||
n of men in the study population | Â | 5601 | 570 | 366 | 4485 | 1074 | 978 |
Mean age at diagnosis | Â | 67 | 70 | 70 | 67 | 68 | 67 |
PCa deaths | Â | 624 (11.1%) | 65 (11.4%) | 39 (10.7%) | 509 (11.3%) | 121 (11.3%) | 98 (10.0%) |
| Â | Median age at death (years) | 73 | 76** | 76** | 72 | 75** | 74** |
Median follow-up from diagnosis to PCa death (years) | Â | 4.5 | 4.5 | 4.5 | 3.9 | 4.8 | 5.8 |
EAU prostate cancer risk-groupb | |||||||
| Â | High-grade | 1661 (29.6%) | 181 (31.8%) | 109 (29.8%) | 1353 (30.2%) | 330 (30.7%) | 268 (27.4%) |
Low-/Intermediate-grade | 3940 (70.3%) | 389 (68.2%) | 257 (70.2%) | 3132 (69.8%) | 744 (69.3%) | 710 (72.6%) | |
Primary therapya | |||||||
| Â | Radical prostatectomy | 1575 (28.1%) | 38 (6.7%)** | 39 (10.7%)** | 1141 (25.4%) | 203 (18.9%)** | 308 (31.5%)** |
EBRT | 2019 (36.0%) | 255 (44.7%) | 149 (40.7%) | 1647 (36.7%) | 444 (41.3%) | 332 (33.9%) | |
Hormonal treatment | 2197 (39.2%) | 303 (53.2%)** | 169 (46.2%)** | 1814 (40.4%) | 490 (45.6%)** | 365 (37.3%)** | |
Active surveillance or watchful waiting | 957 (17.1%) | 113 (19,8%) | 82 (22.4%) | 796 (17.7%) | 195 (18,2%) | 161 (16.5%) | |
Use of other medication | |||||||
| Â | Statin users | 2443 (43.6%) | 346 (60.7%)** | 270 (73.8%)** | 1825 (40.7%) | 607 (56.5%)** | 627 (64.1%)** |
Anti-diabetic drug users | 1024 (18.3%) | 158 (27.7%)** | 92 (25.1%) | 780 (17.4%) | 277 (25.8%)** | 217 (22.2%)** | |
Anti-hypertensive drug users | 3868 (69.1%) | 540 (94.7%)** | 340 (92.9%)** | 2966 (66.1%) | 998 (92.9%)** | 784 (80.2%)** | |
NSAID users | 4806 (85.8%) | 487 (85.4%) | 343 (93.7%)** | 3800 (84.7%) | 935 (87.1%) | 901 (92.1%)** | |
Alpha-blocker users | 2509 (44.8%) | 320 (56.1%)** | 203 (55.5%)** | 2017 (45.0%) | 536 (49.9%) | 479 (49.0%) | |
Aspirin users | 623 (11.1%) | 91 (16.0%) | 174 (47.5%)** | 393 (8.8%) | 151 (14.1%)** | 344 (35.2%)** | |
Recorded diagnoses of: | |||||||
| Â | Atrial fibrillation | 404 (7.2%) | 303 (53.2%)** | 27 (7.4%) | 129 (2.9%) | 571 (53.2%)** | 34 (3.5%) |
Thrombotic factors* | 198 (3.5%) | 93 (16.3%)** | 36 (9.8%) | 88 (2.0%) | 169 (15.7%)** | 70 (7.2%)** | |
Charlson Comorbidity Score | |||||||
| Â | 0 | 3469 (61.9%) | 226 (39.6%)** | 127 (34.7%)** | 2955 (65.9%) | 449 (41.8%)** | 418 (42.7%)** |
1 | 1093 (19.5%) | 147 (25.8%) | 113 (30.9%) | 822 (18.3%) | 272 (25.3%)** | 259 (26.5%)** | |
2 | 1039 (18.6%) | 197 (34.6%)** | 126 (34.4%)** | 708 (15.8%) | 353 (32.9%)** | 301 (30.8 %)** | |